对临床局限性前列腺癌主动监测的系统综述:为纳入中危疾病、纳入与监测时的活检特征及重复活检策略制定推荐
该系统性综述纳入1990年1月至2020年10月发表的333项研究、375个主动监测方案、264852例患者,旨在为中危疾病纳入、活检特征及重复活检策略制定推荐。结论建议:MRI非强制或未使用时,低体积ISUP 2或另一单一项中危因素可考虑主动监测,ISUP 3应排除;2年内行方案性确认活检,前10年至少每3年行方案性重复活检;低危但活检范围较广者需密切监测。
要点
- 低体积ISUP 2(阳性针数≤3且单针癌累及≤50%)或另一单一项中危因素可考虑主动监测,ISUP 3应排除。
- 方案性确认活检应在2年内完成,前10年方案性重复活检至少每3年一次。
- 低危但重复系统活检显示阳性针数>3或单针最大累及>50%者应密切监测不良特征证据。
核心结论
- 对于MRI使用非强制或未使用的主动监测方案,推荐:低体积ISUP 2或另一单一项中危疾病可考虑主动监测,ISUP 3应排除;2年内行方案性确认活检,前10年至少每3年行方案性重复活检;低危但活检范围较广者密切监测不良特征,ISUP 2伴针阳性率和/或累及增加至类似阈值者应重新分类。
研究设计与样本
- 遵循PRISMA、方案驱动的定性系统综述,纳入1990年1月至2020年10月发表的主动监测方案,共17 011篇文章中纳入333项研究、375个方案、264 852例患者。
主要发现
- 仅少数方案在招募(n=17)、随访(n=47)和重新分类(n=26)中使用磁共振成像(MRI)。
- 超过50%的方案纳入中危或高危疾病患者,44.1%的方案排除阳性针数超过3针的低危患者,39%的方案排除单针癌累及(CI)>50%的患者。
- ≥80%的方案强制要求确认性经直肠超声活检;72%(n=189)的方案强制要求方案性重复活检,其中20%每年进行、25%每2年进行。
- 仅27个方案(10.3%)强制要求触发活检,其中74%将MRI上的进展或变化定义为重复活检的触发因素。
关键数值与推荐
- 推荐:低体积ISUP 2(阳性针数≤3且单针癌累及≤50%)或另一单一项中危疾病可考虑主动监测,ISUP 3应排除。
- 推荐:方案性确认性前列腺活检应在2年内进行,前10年方案性监测重复活检至少每3年一次。
- 推荐:招募时为低体积、低危疾病者,若重复系统活检显示阳性针数>3或单针最大累及>50%,应密切监测不良特征(如升级)的证据;ISUP 2疾病伴针阳性率和/或累及增加至类似阈值者应重新分类。
临床怎么用
- 对于MRI非强制或未使用的主动监测方案,可按上述推荐选择纳入患者、安排确认与重复活检及监测阈值。
局限性
- 未评估临床有效性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is uncertainty regarding the most appropriate criteria for recruitment, monitoring, and reclassification in active surveillance (AS) protocols for localised prostate cancer (PCa). OBJECTIVE: To perform a qualitative systematic review (SR) to issue recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and repeat biopsy strategy. EVIDENCE ACQUISITION: A protocol-driven, Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-adhering SR incorporating AS protocols published from January 1990 to October 2020 was performed. The main outcomes were criteria for inclusion of intermediate-risk disease, monitoring, reclassification, and repeat biopsy strategies (per protocol and/or triggered). Clinical effectiveness data were not assessed. EVIDENCE SYNTHESIS: Of the 17 011 articles identified, 333 studies incorporating 375 AS protocols, recruiting 264 852 patients, were included. Only a minority of protocols included the use of magnetic resonance imaging (MRI) for recruitment (n = 17), follow-up (n = 47), and reclassification (n = 26). More than 50% of protocols included patients with intermediate or high-risk disease, whilst 44.1% of protocols excluded low-risk patients with more than three positive cores, and 39% of protocols excluded patients with core involvement (CI) >50% per core. Of the protocols, ≥80% mandated a confirmatory transrectal ultrasound biopsy; 72% (n = 189) of protocols mandated per-protocol repeat biopsies, with 20% performing this annually and 25% every 2 yr. Only 27 protocols (10.3%) mandated triggered biopsies, with 74% of these protocols defining progression or changes on MRI as triggers for repeat biopsy. CONCLUSIONS: For AS protocols in which the use of MRI is not mandatory or absent, we recommend the following: (1) AS can be considered in patients with low-volume International Society of Urological Pathology (ISUP) grade 2 (three or fewer positive cores and cancer involvement ≤50% CI per core) or another single element of intermediate-risk disease, and patients with ISUP 3 should be excluded; (2) per-protocol confirmatory prostate biopsies should be performed within 2 yr, and per-protocol surveillance repeat biopsies should be performed at least once every 3 yr for the first 10 yr; and (3) for patients with low-volume, low-risk disease at recruitment, if repeat systematic biopsies reveal more than three positive cores or maximum CI >50% per core, they should be monitored closely for evidence of adverse features (eg, upgrading); patients with ISUP 2 disease with increased core positivity and/or CI to similar thresholds should be reclassified. PATIENT SUMMARY: We examined the literature to issue new recommendations on active surveillance (AS) for managing localised prostate cancer. The recommendations include setting criteria for including men with more aggressive disease (intermediate-risk disease), setting thresholds for close monitoring of men with low-risk but more extensive disease, and determining when to perform repeat biopsies (within 2 yr and 3 yearly thereafter).
引用
- Willemse PM, Davis NF, Grivas N, et al. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. Eur Urol. 2021. PMID: 34980492. doi:10.1016/j.eururo.2021.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。